U.S. Molecular Diagnostics Market To Reach $8.46 Billion By 2030

U.S. Molecular Diagnostics Market Growth & Trends

The U.S. molecular diagnostics market size is expected to reach USD 8.46 billion by 2030, registering a CAGR of 4.82% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market growth is attributed to increasing awareness of the benefits of adopting molecular diagnostics tests, such as early and rapid detection of viruses and bacteria. Moreover, the ease of access owing to a well-established healthcare sector coupled with favorable reimbursement policies is anticipated to drive the market growth over the forecast period.

Moreover, prominent players in the industry are investing in the technological advancement of molecular diagnostics techniques to develop solutions capable of reducing human effort and delivering instant results. For instance, QIAGEN launched the EZ2 Connect MDx platform for its application in diagnostic laboratories. The platform is equipped with a high degree of automation to purify RNA & DNA from 24 samples with a turnaround time of 30 minutes.

Developments in rapid detection assays are anticipated to support the market growth. These tests have revolutionized the market by accelerating decision-making and reducing turnaround time for decentralized testing. Numerous players are developing assays and molecular diagnostic systems. Digene HC2 GC-ID DNA test for the diagnosis of Neisseria gonorrhea, & Chlamydia trachomatis by Qiagen and ResistancePlus MG FleXible for the diagnosis of Mycoplasma genitalium with macrolide-resistance identification by Danaher Corporation (Cepheid) are examples of such products.

Major players in the market such as Abbott, Siemens Healthcare GmbH, QIAGEN, F. Hoffmann-La Roche Ltd, Danaher, Thermo Fisher Scientific, Inc., Hologic Inc., and BD, are adopting various strategies to enhance their product penetration and expand their customer base. For instance, in January 2023, Thermo Fisher Scientific and AstraZeneca entered into a collaboration to develop a blood-based and solid tissue companion diagnostic test for Tagrisso.

The COVID-19 pandemic has positively impacted the industry by encouraging players to develop rapid and novel diagnostic kits capable of detecting coronavirus. This has resulted in positive revenue growth for major market players operating in the infectious disease segment. For instance, Thermo Fisher Scientific reported 150% revenue growth owing to the rising demand for diagnostics offerings in April 2021. However, the rising adoption of vaccination in the region is anticipated to reduce the demand for COVID-19 testing over the forecast period.

 Request a free sample copy or view report summary: U.S. Molecular Diagnostics Market Report

U.S. Molecular Diagnostics Market Report Highlights

• Based on disease, the respiratory disease segment dominated the market in 2022. The growth is attributed to the increasing prevalence of respiratory infections coupled with the increasing awareness regarding the availability of diagnostic tests for diagnosing and treating infections

• Based on end-use, the hospital core laboratory held the largest share in 2022 and is anticipated to grow at the fastest CAGR over the forecast period owing to the increasing prevalence of infections, such as MRSA, Staphylococcus aureus (SA), and enterovirus

• Major industry players adopt different strategies such as new product launches, collaborations, acquisitions, and expansions to enhance their product penetration and gain a larger consumer base

U.S. Molecular Diagnostics Market Segmentation

Grand View Research has segmented the U.S. molecular diagnostics market based on disease, and end-use:

U.S. Molecular Diagnostics Disease Outlook (Revenue, USD Million, 2018 - 2030)

• Healthcare-associated Infections (HAI)

  • Methicillin-resistant Staphylococcus Aureus

  • Staphylococcus Aureus

  • Enterovirus

  • Clostridioides Difficile

  • Van A

  • Sepsis Panel

• Respiratory

  • Flu

  • Respiratory Syncytial Virus

  • Paraflu

  • Multidrug-resistant Tuberculosis

  • Mycobacterium Avium-intracellulare

  • Group A Streptococcal

  • Adenovirus

  • Human Metapneumovirus

  • Rhinoviruses

  • Middle East Respiratory Syndrome Coronavirus

  • Tuberculosis

  • Severe Acute Respiratory Syndrome Coronavirus 2

  • Human Bocavirus-Infection

  • Bordetella

  • Mycoplasma Pneumonia

  • Respiratory Panels

• Gastrointestinal (GI)

  • Norovirus

  • Helicobacter pylori

  • Shiga Toxin

  • GI Parasite Panel

  • GI Bacterial Panel

  • GI Viral Panel

  • GI Panels

• Women’s Health/STI

  • Chlamydia trachomatis (CT)/Neisseria Gonorrhoeae (NG)

  • Trichomonas Vaginalis

  • Mycoplasma Genitalium

  • Human Papillomavirus

  • Bacterial Vaginosis

  • Gonorrhoea Colloquially

  • Mycoplasma Genitalium Resistance

  • Herpes Simplex Virus

  • Group B Streptococcus

• Immunocompromised

  • Cytomegalovirus

  • Epstein-barr virus

  • Varicella-zoster Virus

  • BK virus

• Virology

  • Human Immunodeficiency Viruses

  • Hepatitis C Virus

  • Hepatitis B Virus

  • Hepatitis E Virus

• Other Targets

  • Babesia

  • Zika

  • West Nile Virus

  • Chikungunya Virus/dengue Virus

  • Enhancer of zeste homolog 2

  • PIK3CA

  • Malaria

  • Monkeypox Virus

• Other Panels

  • Meningitis Panel

  • Lyme Panel

  • UTI Panel

• Oncology

  • Microsatellite Instability

  • B-raf

  • Epidermal Growth Factor Receptor

  • Kirsten RAT SARCOMA VIRUS

  • Others

U.S. Molecular Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Core Laboratory

• Hospital Alternative Sites

• Decentralized Test Sites

• Reference Lab

List of Key Players in the U.S. Molecular Diagnostics Market

• Abbott

• Siemens Healthcare GmbH

• QIAGEN

• F. Hoffmann-La Roche Ltd

• Quest Diagnostics Incorporated

• Danaher

• Thermo Fisher Scientific, Inc.

• Hologic Inc.

• BD

• Charles River Laboratories

• Bio-Rad Laboratories, Inc.

• Illumina, Inc.

• Agilent Technologies, Inc.